{"title":"The Evaluation of Favipiravir Utilization and Clinical Outcome of Inpatients Covid-19 in Secondary Care Hospital, Central Java","authors":"Nialiana Endah Endriastuti, Heny Ekowati, Masita Wulandari Suryoputri","doi":"10.22146/ijp.5274","DOIUrl":null,"url":null,"abstract":"Coronavirus Disease 2019 (COVID-19) is a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The favipiravir is one of the antiviral treatments for COVID-19. There has been limited research done on favipiravir in Indonesia, and there is controversy on the drug's efficacy. This study aims to determine the utilization of favipiravir affected patients with COVID-19. This study was a retrospective data collection method and an observational study. The information was collected from the medical reports of confirmed COVID-19 patients between in March 2020 and June 2021 at the Secondary Care Hospital in Banyumas Regency, Central Java Province, Indonesia. By comparing clinical symptoms before and after using favipiravir, the results of temperature, respiratory rate, and cough symptom parameters were used to evaluate the effects of using favipiravir on clinical symptoms. The total number of 250 patients were qualified the inclusion criteria consisted of 90 patients with severity of illness in mild level, 101 patients had moderate level, and 59 patients with severe level. Most patients reported symptoms of coughing, shortness of breath, weakness, fever, and nausea. The majority of favipiravir patients (n=200; 80%) initiated with a dose of 1600 mg/12 hours, followed by a dose of 600 mg/12 hours, with the longest length of therapy (8-14 days) (n=145; 58%). At all grades of disease severity, statistical analysis of patients showed the significant improvement in cough, fever, and respiratory rate after taking favipiravir (p=0.0001). In conclusion, favipiravir may have beneficial effects on COVID-19 patients in all grade severity of illness.","PeriodicalId":13520,"journal":{"name":"INDONESIAN JOURNAL OF PHARMACY","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INDONESIAN JOURNAL OF PHARMACY","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22146/ijp.5274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Coronavirus Disease 2019 (COVID-19) is a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The favipiravir is one of the antiviral treatments for COVID-19. There has been limited research done on favipiravir in Indonesia, and there is controversy on the drug's efficacy. This study aims to determine the utilization of favipiravir affected patients with COVID-19. This study was a retrospective data collection method and an observational study. The information was collected from the medical reports of confirmed COVID-19 patients between in March 2020 and June 2021 at the Secondary Care Hospital in Banyumas Regency, Central Java Province, Indonesia. By comparing clinical symptoms before and after using favipiravir, the results of temperature, respiratory rate, and cough symptom parameters were used to evaluate the effects of using favipiravir on clinical symptoms. The total number of 250 patients were qualified the inclusion criteria consisted of 90 patients with severity of illness in mild level, 101 patients had moderate level, and 59 patients with severe level. Most patients reported symptoms of coughing, shortness of breath, weakness, fever, and nausea. The majority of favipiravir patients (n=200; 80%) initiated with a dose of 1600 mg/12 hours, followed by a dose of 600 mg/12 hours, with the longest length of therapy (8-14 days) (n=145; 58%). At all grades of disease severity, statistical analysis of patients showed the significant improvement in cough, fever, and respiratory rate after taking favipiravir (p=0.0001). In conclusion, favipiravir may have beneficial effects on COVID-19 patients in all grade severity of illness.
期刊介绍:
The journal had been established in 1972, and online publication was begun in 2008. Since 2012, the journal has been published in English by Faculty of Pharmacy Universitas Gadjah Mada (UGM) Yogyakarta Indonesia in collaboration with IAI (Ikatan Apoteker Indonesia or Indonesian Pharmacist Association) and only receives manuscripts in English. Indonesian Journal of Pharmacy is Accredited by Directorate General of Higher Education. The journal includes various fields of pharmaceuticals sciences such as: -Pharmacology and Toxicology -Pharmacokinetics -Community and Clinical Pharmacy -Pharmaceutical Chemistry -Pharmaceutical Biology -Pharmaceutics -Pharmaceutical Technology -Biopharmaceutics -Pharmaceutical Microbiology and Biotechnology -Alternative medicines.